Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents

Assessment of the Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents : A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial

The purpose of this study is to compare the efficacy and tolerability between clopidogrel resinate and clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD equivalents.

Inclusion Criteria:

• Korean men and women aged 20 to 85 years with coronary heart disease (CHD) or CHD equivalent patients
• Atherosclerotic plaques in coronary computed tomography (CT) or angiography or
• History of PCI or coronary artery bypass graft surgery (CABG) > one year or
• Diabetes mellitus (including type I and type II) or
• Confirmed carotid atherosclerotic plaque with sonography, CT or angiography or
• History of peripheral artery disease or
• History of cerebrovascular disease

Exclusion Criteria:

• Patients who had history of PCI within one year
• Patients who used concomitant anticoagulants
• Patients who had hypersensitivity to aspirin or clopidogrel, serious bleeding tendency, history of intracranial hemorrhage, sign of active bleeding, uncontrolled hypertension
• Chronic alcoholism or drug addiction
• Women who were pregnant or breastfeeding or who were not using an effective method of contraception
• The use of glycoprotein IIb/IIIa inhibitor, daily NSAIDs, lipid lowering agent (except atorvastatin), or substances with possible interactions with the study drug